Anyone researching thymogen quickly runs into a gap between its lab reputation and its regulatory reality. This overview separates what is chemically known from what remains unverified in humans.
Key takeaways
- Thymogen is classified as an unapproved research compound with no FDA-approved label.
- It is a synthetic dipeptide with the molecular formula C16H19N3O5 and a molecular weight of 333.34.
- No registered clinical trials for thymogen were found at the time of this review.
- The compound is identified in PubChem under CID 100094 for reference purposes.
What thymogen is
Thymogen is a small synthetic peptide built from two amino acid units, giving it the compact structure of a dipeptide rather than a larger protein chain. Its chemical makeup corresponds to the formula C16H19N3O5, with a molecular weight of about 333.34. No pharmaceutical label, approved brand name, or defined mechanism of action has been established for this compound. It exists in scientific literature and chemical databases as a research substance rather than as an approved drug.
Regulatory and trial status
Thymogen carries unapproved research status. It has not been reviewed or authorized by the FDA for any medical use, and no drug label currently exists for it. A search of clinical trial registries found zero registered studies involving this compound. This absence means there is no publicly documented clinical trial program evaluating thymogen in humans at this time.